4:50 PM
 | 
Sep 14, 2010
 |  BC Extra  |  Clinical News

GSK561679 misses depression endpoint

Neurocrine Biosciences Inc. (NASDAQ:NBIX) said GSK561679 missed the primary endpoint in a double-blind U.S. Phase II trial to treat major depressive disorder (MDD). The corticotropin-releasing factor...

Read the full 116 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >